<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01248988</url>
  </required_header>
  <id_info>
    <org_study_id>114469</org_study_id>
    <nct_id>NCT01248988</nct_id>
  </id_info>
  <brief_title>Post Marketing Surveillance of Synflorix Vaccine Safety Among Infants in Korea</brief_title>
  <official_title>Safety of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal-protein D-diphtheria Toxoid-tetanus Toxoid Conjugate (10PN-PD-DiT) Vaccine, Synflorix When Administered According to the Approved Prescribing Information in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect safety information following routine vaccination with
      Synflorix™ among infants in Korea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale for the protocol amendment: The therapeutic indication for Synflorix in Korea has
      been updated. The protocol is being amended to reflect this update.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of unexpected adverse events</measure>
    <time_frame>During the 30-day (Day 0 - Day 29) follow-up period after each vaccine dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of expected adverse events</measure>
    <time_frame>During the 30-day (Day 0 - Day 29) follow-up period after each vaccine dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of serious adverse events</measure>
    <time_frame>From the first dose in the study up to 30 days (Day 0 - Day 29) after the last dose.</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">622</enrollment>
  <condition>Infections, Streptococcal</condition>
  <arm_group>
    <arm_group_label>Synflorix Group</arm_group_label>
    <description>Infants and children who received at least one dose of Synflorix™ as a part of routine practice at a private clinic or hospital</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Synflorix™ Data collection</intervention_name>
    <description>Safety monitoring: recording of adverse events during using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.</description>
    <arm_group_label>Synflorix Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Infants and children who receive at least one dose of Synflorix as a part of routine
        practice at a private clinic or hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that their parent(s)/Legally Acceptable
             Representatives can and will comply with the requirements of the protocol.

          -  Korean male or female subjects whose age while receiving the first vaccination with
             Synflorix is 6 weeks - 5 years.

          -  Written, signed or thumb-printed informed consent obtained from the parent(s)/ Legally
             Acceptable Representative(s) of the child. Where parent(s)/Legally acceptable
             representatives are illiterate, the consent form will be countersigned by a witness.

        Exclusion Criteria:

          -  At the time of Post Marketing Surveillance entry, the contraindications and
             precautions of use indicated in the local Prescribing Information should be checked
             and the infant must not be included in the Post Marketing Surveillance if there is any
             contraindication. Any changes in the locally approved Prescribing Information must be
             implemented immediately.

          -  Subjects who receive any investigational or non-registered pneumococcal vaccine 30
             days prior to the study start will not be enrolled. Subjects who had previous
             administration of a pneumococcal vaccine other than Synforix will not be enrolled into
             the study.

          -  A male or female children &gt;= 5 years of age at study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Suwon, Kyonggi-do</city>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2010</study_first_submitted>
  <study_first_submitted_qc>November 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2010</study_first_posted>
  <last_update_submitted>January 12, 2017</last_update_submitted>
  <last_update_submitted_qc>January 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumococcal vaccine</keyword>
  <keyword>Safety</keyword>
  <keyword>Synflorix</keyword>
  <keyword>Pneumococcal diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Streptococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

